Last Updated on 10 seconds ago by TodayWhy Editorial
Declassification Explainer
On June 12, 2026, DNI Tulsi Gabbard declassified intelligence revealing U.S. funding of 120+ biolabs in 30+ countries. Here’s what the program was, why it existed, and why the public didn’t know.
Key Facts at a Glance
- On June 12, 2026, DNI Tulsi Gabbard released newly declassified intelligence on U.S. biolab funding.
- The documents confirm U.S. government funding of more than 120 biological laboratories in over 30 countries.
- 40 of those facilities are in Ukraine — a country currently at war with Russia.
- The program dates to 1991 and was originally designed to secure Soviet-era biological weapons stockpiles.
- The ODNI stated the information had been “knowingly withheld” from the American public.
- Gabbard is leaving office June 30, 2026. The release is part of a broader pre-departure declassification effort.
What Happened on June 12, 2026
The morning of June 12, 2026, outgoing Director of National Intelligence Tulsi Gabbard posted a one-sentence announcement on X that stopped many national security watchers in their tracks: she was releasing never-before-seen intelligence revealing U.S. government funding for more than 120 biological laboratories across more than 30 countries.
The accompanying ODNI press release was blunt. It stated that evidence of the labs’ existence, locations, and funding history had been “knowingly withheld” from the American public. It accused “politicians, so-called health professionals,” and members of the Biden administration’s national security team of lying about the labs’ existence and threatening those who sought to expose them.
The declassified slides themselves — approved for release in April 2026 — were published directly on the ODNI’s website. For millions of Americans who had heard the “U.S. biolabs” claim dismissed as Russian disinformation since 2022, the release raised an urgent question: what is actually going on here?
What Are These Biolabs, Actually?
The phrase “biolab” conjures images of covert weapons programs. The reality is more layered — and more complicated.
The facilities in question are not, as a category, secret underground bunkers. Most are public health laboratories: disease surveillance centers, veterinary diagnostic facilities, and pathogen repositories that track naturally occurring outbreaks. Many had been operating for decades before the U.S. became involved.
What the U.S. funded was their modernization. Upgraded biosafety equipment. Better pathogen storage. Training programs for local scientists. The goal, according to official DoD documents, was to reduce the risk that dangerous pathogens could be misused, stolen, or accidentally released.
However, the ODNI’s June 2026 disclosure adds a significant qualifier: some of these facilities have engaged — or are currently engaging — in research involving “hazardous and highly contagious pathogens,” including, in some cases, gain-of-function research, “with very little visibility or oversight.” That qualifier is at the center of the controversy.
Cold War Origins: The Nunn-Lugar Program
To understand why the U.S. was funding laboratories in Ukraine, Kazakhstan, Georgia, and dozens of other countries, you have to go back to 1991.
When the Soviet Union collapsed, it left behind an enormous and barely secured legacy of weapons-grade materials: nuclear warheads, chemical weapon stockpiles, and — critically — biological research facilities that had worked on some of the most dangerous pathogens ever studied. At the height of the Cold War, Soviet programs had produced extraordinary quantities of weaponized biological agents.
Congress recognized the proliferation risk immediately. In 1991, Senators Sam Nunn (D-GA) and Richard Lugar (R-IN) authored legislation creating the Cooperative Threat Reduction (CTR) program — also known as Nunn-Lugar — housed within the Department of Defense. Its mission: help former Soviet states secure or destroy inherited weapons materials before they could fall into dangerous hands.
The biological component — the Biological Threat Reduction Program (BTRP), administered by the Defense Threat Reduction Agency (DTRA) — eventually extended that mission to laboratories in countries as geographically diverse as Armenia, Azerbaijan, Georgia, Kazakhstan, Uzbekistan, and, beginning in 2005, Ukraine.
Ukraine: Why 40 Labs in a War Zone?
Ukraine became a focus of the CTR program for a straightforward historical reason: it inherited a disproportionately large share of Soviet-era biological research infrastructure when it gained independence in 1991. Facilities that had operated within the Soviet anti-plague network — tracking endemic diseases across Central Asia and Eastern Europe — were suddenly Ukrainian national institutions with limited funding and deteriorating security.
The U.S.-Ukraine bilateral agreement formalizing the biological cooperation was signed in August 2005. Present at the signing was a two-senator U.S. delegation: Richard Lugar and a junior senator from Illinois named Barack Obama.
Under that agreement, the U.S. provided funding and equipment to Ukrainian public health and veterinary laboratories. The facilities remained Ukrainian-owned and Ukrainian-operated. The legal framework gave the DoD audit rights over any facility receiving assistance. DTRA has maintained publicly that none of the facilities it supported conducted bioweapons research or gain-of-function experiments.
The problem — and one the ODNI’s 2026 disclosure leans into — is that Russia’s invasion of Ukraine starting in February 2022 turned those laboratories into a live security concern. Intelligence assessments, including at least one now declassified, warned that a veterinary facility in Kharkiv — a city that became a major combat zone — likely housed dangerous pathogens and remained vulnerable to seizure or damage. That is a scenario the CTR program was originally designed to prevent.
Why Was the Full Scope Hidden?
This is the question the ODNI’s release answers most provocatively — and most incompletely.
The existence of the CTR program and its biolab component was never classified. Congressional budget documents, DoD fact sheets, and peer-reviewed academic work on biosecurity had described the program for years. When Russia began amplifying “U.S. bioweapons lab” claims in early 2022, fact-checkers and the State Department pushed back citing this public record.
What appears to have been withheld is the full scope: the comprehensive list of countries, the specific lab locations, the nature of research conducted at individual facilities, and — most critically — the internal intelligence assessments about security vulnerabilities and oversight gaps.
The ODNI’s framing is that this was deliberate political suppression. Independent analysts note a different possibility: that national security classification of specific pathogen locations is standard practice, unrelated to covering up wrongdoing, and that the gap between what was publicly known and what was classified was narrower than the ODNI framing suggests.
Both things can be true simultaneously. The CTR program’s broad outline was knowable. The detailed intelligence picture — including the security warnings about Kharkiv — was not.
The Gain-of-Function Question
Gain-of-function (GoF) research involves modifying pathogens — typically to make them more transmissible or more virulent — for the stated purpose of studying how diseases might evolve and how to develop countermeasures. The practice became intensely controversial during the COVID-19 pandemic, when questions arose about whether U.S.-funded research at the Wuhan Institute of Virology had contributed to the origin of SARS-CoV-2.
The ODNI’s June 2026 disclosure explicitly states that some U.S.-funded overseas biolabs “are currently or have previously engaged” in GoF research “with very little visibility or oversight.” This is a significant claim that goes beyond what DTRA has publicly acknowledged.
It is worth noting what the disclosure does not say. It does not provide specific evidence of which facilities conducted GoF research, under what protocols, or with what results. The claim is made in the ODNI press release and in the declassified slide deck — which, at time of publication, was available on the ODNI website — but without the granular documentation that would allow independent verification.
President Trump signed Executive Order 14292 in May 2025 banning federal funding for GoF research globally. The June 2026 ODNI release was framed in part as evidence of why that order was necessary.
Why Gabbard Declassified Now
Gabbard announced her resignation as DNI on May 22, 2026, citing her husband Abraham’s diagnosis with a rare illness. Her departure is effective June 30, 2026.
In her final weeks, she undertook an aggressive pre-departure declassification campaign. Beyond the biolab documents, she was also working to release intelligence on COVID-19 pandemic origins and Anomalous Health Incidents (Havana Syndrome) before her exit. She had previously declassified more than half a million pages of government documents during her tenure, along with details of the Biden administration’s domestic counterterrorism strategy.
Critically, the biolab slides themselves were formally declassified on April 23, 2026 — nearly two months before their public release. The delay between declassification and publication suggests the release was a deliberate strategic decision timed to her final weeks in office.
Critics have noted that framing the release around political accusations — naming Fauci and the Biden national security team by implication — gives the disclosure a partisan character that complicates its reception as a straightforward transparency exercise.
What the Disclosure Actually Changes
Several things are now clearer than they were on June 11, 2026.
First, the U.S. did fund a significantly larger global network of biological laboratories than the public generally understood, even if the CTR program’s existence was technically not secret. The number — 120 labs in 30+ countries — had not been publicly confirmed by the U.S. government before this release.
Second, some of those facilities conducted, or are conducting, research that raises legitimate biosafety questions — including apparent gain-of-function work in contexts with limited oversight. This is the most substantively new claim in the release, and it warrants independent congressional scrutiny.
Third, the security vulnerability of labs in active war zones — particularly Ukraine — is a real and documented intelligence concern, not merely a Russian propaganda talking point. The classified assessments about the Kharkiv facility predate Russia’s invasion.
What has not changed: there is no declassified evidence that any of the 120+ facilities were bioweapons programs. The CTR program’s core purpose — securing Cold War pathogen stockpiles — remains the documented mission. The gap between “U.S.-funded public health labs with oversight problems” and “covert U.S. bioweapons network” is significant, and nothing in the June 12 release closes it.
“Despite the obvious potential for catastrophic global impact research on dangerous pathogens in biolabs can have, politicians, so-called health professionals like Dr. Fauci, and entities within the Biden administration’s national security team lied to the American people about the existence of U.S.-funded and supported biolabs.”— DNI Tulsi Gabbard, ODNI Press Release No. 10-26, June 12, 2026
Gabbard has directed the Intelligence Community to begin increased collection on overseas lab activities. Her successor as DNI — not yet confirmed at time of publication — will inherit both the expanded intelligence mandate and the political fallout from the disclosure.
Frequently Asked Questions
Why did the U.S. fund biolabs overseas?
The funding originated from the Cooperative Threat Reduction (CTR) program, created by Congress in 1991 after the Soviet Union collapsed. The goal was to secure dangerous Soviet-era biological, chemical, and nuclear materials left unsecured across multiple newly independent countries.
How many U.S.-funded biolabs exist, and where are they?
According to the ODNI declassification of June 12, 2026, the U.S. has funded more than 120 biological laboratories in over 30 countries. Around 40 of those facilities are located in Ukraine, where the program has operated since 2005.
Are these biolabs bioweapons laboratories?
The U.S. Department of Defense has consistently maintained that the labs are public health and biosafety facilities, not bioweapons sites. They are owned and operated by host countries under bilateral agreements. The ODNI’s June 2026 release states that some facilities have conducted gain-of-function research with limited oversight — a claim that warrants independent verification.
Why was this information classified?
The ODNI stated that the existence, locations, and funding history of the labs had been “knowingly withheld” from the public. Standard national security practice classifies specific pathogen locations and vulnerability assessments. The June 2026 release declassified intelligence assessments that included security warnings about specific facilities — information that had not been publicly confirmed.
Why did Gabbard declassify the documents now?
Gabbard announced her resignation as DNI effective June 30, 2026. The disclosure is part of a broader declassification push she undertook in her final weeks, which also included COVID-19 pandemic documents and Havana Syndrome (Anomalous Health Incidents) intelligence files.
What happens next following the ODNI biolab disclosure?
Gabbard has directed increased Intelligence Community collection on overseas labs. The release is also expected to intensify Congressional scrutiny of the Defense Threat Reduction Agency and its Biological Threat Reduction Program, particularly regarding gain-of-function research oversight and security protocols in conflict zones.
Sources: ODNI Press Release No. 10-26 (June 12, 2026) · U.S. Mission Geneva — CTR Fact Sheet · Arms Control Association (2005)
TodayWhy.com publishes explainer journalism on current events, geopolitics, and science. Article reflects information available as of June 13, 2026.